Logo

VINC

Vincerx Pharma, Inc.

VINC

Vincerx Pharma, Inc. • NASDAQ
$0.01 ▲ 0.00% (+0.00)
Market Cap $62811
52w High $10.38
52w Low $0.00
Dividend Yield 0%
P/E 0
Volume 22
Outstanding Shares 5.23M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2025 $0 ▼ $3.334M ▼ $-5M ▲ 0% ▲ $-0.96 ▼ $-3.334M ▲
Q4-2024 $1.068M ▲ $8.826M ▲ $-7.994M ▼ -748.502% ▼ $4.22 ▲ $-8.545M ▼
Q3-2024 $0 $7.793M ▲ $-7.843M ▼ 0% $-1.41 ▼ $-7.518M ▼
Q2-2024 $0 $7.366M ▲ $-1.808M ▲ 0% $-0.32 ▲ $-7.096M ▲
Q1-2024 $0 $7.214M $-12.429M 0% $-2.11 $-7.214M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2025 $4.437M ▼ $4.686M ▼ $2.62M ▼ $2.066M ▼
Q4-2024 $4.987M ▼ $8.005M ▼ $5.281M ▼ $2.724M ▼
Q3-2024 $10.086M ▼ $14.947M ▼ $5.839M ▼ $9.108M ▼
Q2-2024 $16.401M ▲ $21.527M ▲ $6.079M ▼ $15.448M ▲
Q1-2024 $5.11M $11.083M $11.705M $-622K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2025 $-5M ▲ $-4.454M ▲ $0 ▼ $3.856M ▲ $-547K ▼ $-4.454M ▲
Q4-2024 $-7.994M ▼ $-6.181M ▲ $7.175M ▲ $985K ▲ $2.039M ▲ $-6.181M ▲
Q3-2024 $-7.843M ▼ $-6.379M ▼ $1.374M ▲ $0 ▼ $-4.978M ▼ $-6.379M ▼
Q2-2024 $-1.808M ▲ $-5.828M ▲ $-8.337M ▼ $17.002M ▲ $2.813M ▲ $-5.828M ▲
Q1-2024 $-12.429M $-7.739M $0 $5K $-7.662M $-7.739M

Five-Year Company Overview

Income Statement

Income Statement Vincerx has been a research-only company with essentially no product or licensing revenue so far. Its income statement is dominated by ongoing operating losses tied to R&D, overhead, and public company costs. Losses have been persistent every year since listing, though they have narrowed somewhat recently as the company has cut back spending. Earnings per share look very weak because the company is small and spreading its fixed costs over a limited base, not because of any collapse in a commercial business. Overall, this is a classic profile of a clinical‑stage biotech: all cost, no revenue, and dependent on outside funding.

Balance Sheet

Balance Sheet The balance sheet is thin and getting lighter. Total assets are small and mostly made up of cash and equivalents, which have steadily declined as losses accumulate. There is effectively no financial debt, which is a positive, but equity has eroded over time as the company burns capital. The lack of liabilities avoids immediate creditor pressure, yet the modest asset base and shrinking equity cushion leave little room for error and likely limit the company’s flexibility without new strategic deals or capital injections.

Cash Flow

Cash Flow Cash flows are consistently negative from operations, reflecting spending on research, clinical development, and corporate expenses without incoming revenue. Capital spending has been minimal, so almost all cash usage is driven by the day‑to‑day running of the business and R&D. Free cash flow has been firmly negative each year, which means the company has been financing itself by drawing down its cash balance and, historically, by raising capital. With the cash runway publicly flagged as short, the cash flow profile underscores urgency: without a deal, financing, or restructuring, the current trajectory is not sustainable.

Competitive Edge

Competitive Edge Scientifically, Vincerx has tried to carve out a niche in advanced cancer therapies, using its VersAptx platform for antibody‑drug and small‑molecule drug conjugates. This gives it some differentiation in how drugs are designed and delivered to tumor cells, and the leadership team has relevant oncology experience. However, the competitive landscape in oncology and ADCs is intense, with many better‑funded players. The company’s small scale, limited resources, and financial distress significantly weaken its practical competitive position, as it may struggle to move assets through trials or to commercial readiness on its own. The exploration of strategic alternatives and potential pivot away from biotech further clouds how enduring its competitive moat really is.

Innovation and R&D

Innovation and R&D On the innovation side, Vincerx has developed a notable technology platform aimed at more precise and potent cancer treatments. Its drug candidates target difficult blood cancers and solid tumors, leveraging specialized linkers and payloads intended to improve both effectiveness and safety versus older approaches. This is intellectually compelling science, and the pipeline includes several differentiated candidates at early and mid stages. But the R&D story is now heavily constrained by funding reality: clinical progress will likely depend on partnerships, out‑licensing, or a buyer, and there is a real possibility that the oncology assets end up separated from the public company if a reverse merger into another industry proceeds.

Summary

Vincerx today is less a traditional operating company and more a collection of promising oncology technologies facing a financial and strategic crossroads. The historical financials show a pure R&D enterprise: no revenue, ongoing losses, shrinking cash, and a very lean balance sheet. The scientific platform and pipeline offer potential value, and the team has relevant drug‑development experience, but these strengths are offset by a short cash runway, delisting risk, and significant uncertainty around future direction. Management is actively pursuing strategic alternatives, including reverse mergers and asset monetization, so the key question is not how the business will grow, but how—and in what structure—its remaining scientific assets will be preserved or realized. Uncertainty is high, and the company’s future shape could look very different from the biotech that exists today.